

Commercial/Healthcare Exchange Step Criteria

Effective: January 31, 2018

Step Therapy Name: Xhance Nasal Spray

Step 1 Agent(s): mometasone furoate nasal spray

Step 2 Agent(s): Xhance (fluticasone propionate) nasal spray

Medication/Class Description:

FDA Approved Indication:

Mometasone furoate nasal spray

a. treatment of nasal polyps in patients ≥ 18 years of age

Xhance nasal spray

a. treatment of nasal polyps in patients ≥ 18 years of age

Nasal polyps is a condition that impacts about 4% of the world's population. Nasal polyps are lesions which occur in the nasal mucosa or paranasal sinuses and can be caused by a number of different conditions, including chronic sinusitis and allergic rhinitis. Overall, the treatment goal for nasal polyps is either a reduction in size or complete elimination of the polyps.

Medications are typically the initial approach; however, surgery may be needed in some cases. Surgery may not provide a permanent solution, though, as polyps tend to recur. Nasal polyp treatment usually starts with medications that can make polyps shrink or disappear. Treatments may include nasal corticosteroids, mometasone furoate (Nasonex) and Fluticasone propionate (Xhance) are the only corticosteroid nasal sprays FDA-approved for the treatment of nasal polyps. Oral and injectable corticosteroids may also be utilized if a nasal corticosteroid is not effective. Oral corticosteroids, such as prednisone, may be used either alone or in combination with a nasal spray. Injectable corticosteroids may be used if nasal polyps are severe.

Required Medical Information:

1. Diagnosis of nasal polyps
2. History of previous therapies tried/failed [documentation required]:

Age Restrictions: 18 years of age or older

Prescriber Restrictions: N/A

Coverage Duration: 12 Months

Exceptions for Stepped Medications:

- A. Patient has history of failure of a Step 1 Agent defined as:
 - a. Failure to decrease nasal polyps either a reduction in size or complete elimination
 - b. Worsening of symptoms due to nasal polyps
- B. Patient has an intolerance or contraindication to a Step 1 Agent defined as (but not limited to):
 - a. Allergic reaction
 - b. Adverse reaction

References:

1. Nasonex[®] [package insert]. Kenilworth, NJ: Schering Corporation; September 2005.
2. Xhance[™] nasal spray [package insert]. Yardley, PA: OptiNose US, Inc. September 2017.

Policy Revision history:

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	1/21/2018
2	Policy Update	Moved to updated template CCI Revision Record: 5/07, 10/10, 4/12, 7/12, 9/12, 4/16, 11/16, 2/17, 1/18	All	2/6/2020